Three-Drug attack on tough ovarian cancers
NCT ID NCT07489300
Summary
This study is testing whether a combination of three drugs—benmelstobart, anlotinib, and cyclophosphamide—can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if this treatment can delay cancer progression and is safe for patients. The trial will enroll 40 people in China who have had their cancer return after previous treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.